伊贝沙坦治疗良性小动脉性肾硬化蛋白尿临床观察  

ONical Observer the Ireat Effect of Irbesartan in Essential Hypertention Patients

作　　者：孙爱华[1] 梅克治[1] 李青[1] 

机构地区：[1]广州市红十字会医院,广州510220

出　　处：《中国医药导刊》2002年第2期127-128,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:观察伊贝沙坦对良性小动脉性肾硬化蛋白尿的效应。方法:所有患者已用除ACEI、ARB以外的降压药至血压≤140/90mmHg。治疗组加予伊贝沙坦150～300mg/d,观察10～12周。对照组用入选前降压药。测定24小时尿蛋白、尿微量白蛋白、尿α_1球蛋白、尿转铁蛋白、尿β_2-M和血β_2-M球蛋白。结果:治疗组蛋白尿改善显著优于对照组。结论:在血压正常情况下,伊贝沙坦对良性小动脉性肾硬化蛋白尿的改善较其它除ACEI、ARB以外的降压药为好。且脉压≥41mmHg与≤40mmHg者治疗效果无显著差异。Objective: To observe the effect of irbesartan on proteinuria in benign arteriolar nephrosclerosis patients.Methods:All pa- tients had received antihypertensive other than ACEI and ABB to keep normal blood pressure,Therapy group were given irbesartan 150-300mg/d for 10-12 weeks.Previous antihypertensive persisted in control group, 24h urine protein, urineai -globulin,urine transfer-rin,urine β2 - Microglobulin and blood β2 - Microglobulin were measured.Results: Proteinuria in therapy group were relieved signficantly compared with controls. Conclusion:In comparison with antihypertensive othe than ACEI and arb,irbesartanimproved proteinuria in essential hypertension patients with normal blood pressure. No significant efficacy difference were found between patients of pulse pressure ≥41mmHg and throe of pulse pressure ≤40mmHg.

关 键 词：伊贝沙坦 良性小动脉性肾硬化 治疗 蛋白尿 原发性高血压 ACEI ARB 

分 类 号：R692.9[医药卫生—泌尿科学]